Inside Myeloma Rounds: Expert Discussion and Updates (Pharmacist)

Credit Available: AAPA, ACPE, CABRN,CME

 

Enroll in this Course

FREE

access until October 28, 2026 12:00 am

 

Enroll Now

Activity Description

This webinar will feature highlights from Myeloma Rounds in Durham, Philadelphia, and San Francisco, that were held in the spring of 2025, as well as highlights of additional clinical updates after the Rounds. Discussion will cover the latest advancements in myeloma, including current and emerging therapies; clinical trials; optimal patient care strategies; disparities and challenges in diagnosis and treatment; and evidence-based treatment approaches. A review of educational resources for you, as well as resources that you can share with your patients will also be provided.

Time to Complete Activity: 1.0 hour

This course is available from:

October 20, 2025 until October 28, 2026

Course Instructors

Ajai Chari, MD (Chair, Myeloma Rounds, San Francisco) Speaker

Director of Multiple Myeloma Program, Co-Director of Clinical Research Hematology/Oncology, Professor of Clinical Medicine, University of California, San Francisco, San Francisco, CA

Edward A. Stadtmauer, MD Speaker

(Chair, Myeloma Rounds, Philadelphia)​ Section Chief, Hematologic Malignancies Roseman, Tarte, Harrow, and Shaffer Families’, President’s Distinguished Professor, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

Cindy Varga, MD Speaker

(Chair, Myeloma Rounds, Durham) Associate Professor, Atrium Health Levine Cancer Institute, Plasma Cell Dyscrasia Division, Department of Hematology and Oncology, Charlotte, NC

Target Audience

This activity is intended for hematologists-oncologists, medical oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients with myeloma.

Learning Objectives
After completing this activity, the participant should be better able to:

• • Describe the latest developments in myeloma, including current and emerging treatments
  • Engage patients and caregivers in clinical trials discussions on newly approved therapies and emerging therapies for myeloma, including combination therapies, CAR T-cell therapy and bi-specific antibodies
  • Explain disparities and challenges in diagnosis and treatment of myeloma
  • Apply evidence-based treatment strategies for optimal patient care
  • Identify patient education and support resources

Accreditation, Credit and Support

In support of improving patient care, this activity has been planned and implemented by Blood Cancer United and Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.​

​Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).​

​For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

Physician Associate

Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: #: JA0007322-9999-25-038-H01-P
Type of Activity: Application

Registered Nursing Credit Designation

Approval for nurses has been obtained by the National Office of Blood Cancer United under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

Interprofessional Continuing Education Credit

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Providers

This activity is provided by Blood Cancer United and Medical Learning Institute Inc, in collaboration with the Association of Cancer Care Centers™ (ACCC).

           

Support Statement

Supported by educational grants from Adaptive Biotechnologies Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Conflicts of Interest Policy

Blood Cancer United and Medical Learning Institute Inc, are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, Blood Cancer United and MLI require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to Blood Cancer United and MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures

Ajai Chari, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: AbbVie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, FORUS, Genentech/Roche, GlaxoSmithKline, Janssen, Karyopharm, Millenium/Takeda, Sanofi/Genzyme

Edward A. Stadtmauer, MD*, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: AbbVie, Amgen, Bristol Myers Squibb, Janssen
Research Funding: AstraZeneca

Cindy Varga, MD (Chair), has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Janssen
Research Funding: ARCELLX/Kite, Janssen, K36

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Blood Cancer United and Medical Learning Institute Inc do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Lauren Berger, MPH, has a financial interest/relationship or affiliation in the form of:
Stock Ownership with Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Organon & Co., Pfizer Inc., and Viatris Inc.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the accredited CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

About this Activity

Blood Cancer United and Medical Learning Institute Inc are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of  Blood Cancer United and Medical Learning Institute Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc.

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact Nicole Dane at ndane@mlieducation.org. 

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at profeducation@bloodcancerunited.org.